Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial

Pott-Júnior, Henrique; Bricks, Guilherme; Grandi, Giuliano; Senise, Jorge Figueiredo; Filho, Adauto Castelo

doi:10.1016/j.cmi.2018.06.007

Cited by 8 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, screening and full‐text assessment resulted in 20 included studies (14 manuscripts and 6 conference abstracts) that reported on SVR12 by DAAs in 7,393 individuals from South American countries (Figure 1). 27‐46 A total of 16 studies were published in English, two in Spanish 40,44 and two in Portuguese 29,33 . In addition, included studies were performed in Brazil (n = 11), Argentina (n = 4), Chile (n = 1), Colombia (n = 1), Peru (n = 1), and international collaborations in South America (n = 2) [Argentina, Chile, Colombia and Uruguay (n = 1); Argentina and Brazil (n = 1)].…”

Section: Resultsmentioning

confidence: 99%

“…Among the studies included in the present meta‐analysis, only two were clinical trials, both performed in Brazil. Pott‐Jr et al published a single centre randomized open‐label study to compare the effectiveness of SOF plus DCV or SIM for 12 weeks, in GT1 patients with advanced fibrosis and without cirrhosis (LSM from 9.6 to 12.5 kPa) [NCT 02624063] 37 . Pessoa et al published a multicentre, phase 3b open‐label single arm clinical trial to evaluate the effectiveness of OBV/PTV/r/DSV ± RBV for 12 weeks in GT1 patients with advanced fibrosis or cirrhosis [NCT 02442271] 34 .…”

Section: Discussionmentioning

confidence: 99%

“…Finally, screening and full-text assessment resulted in 20 included studies (14 manuscripts and 6 conference abstracts) that reported on SVR12 by DAAs in 7,393 individuals from South American countries ( Figure 1). [27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46] A total of 16 studies were published in English, two in Spanish 40,44 and two in Portuguese. 29,33 In addition, included studies were performed in Sofosbuvir/Simeprevir ± Ribavirin (SOF/SIM ± RBV), Sofosbuvir/ Ledipasvir (SOF/LDV) or Ombitasvir/Paritaprevir/Ritonavir + Dasa buvir ± Ribavirin (OBV/PTV/r/DSV ± RBV).…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of direct‐acting agents for chronic hepatitis C treatment in South America: A systematic review and meta‐analysis

Filho

Piedade

Castro

et al. 2020

Journal of Viral Hepatitis

View full text Add to dashboard Cite

The effectiveness of direct-acting agents (DAAs) for hepatitis C treatment in limited-resource settings remains unclear. We estimated the pooled sustained virological response rates of DAA therapy in South America. We searched online databases for studies that reported 12-week sustained virological response (SVR12) to hepatitis C virus (HCV) treatment in individuals living in South America. Pooled SVR12 in intention-to-treat (ITT) and per-protocol were estimated. Additionally, using all studies with available data, the pooled relative risk (RR) of SVR12 using a randomeffects model (DerSimonian-Laird) was estimated to compare effectiveness of DAAs in patients with or without cirrhosis, HIV co-infection or previous HCV therapy. Heterogeneity was assessed using the I 2 statistics. We identified 20 studies [14 manuscripts and 6 conference abstracts] comprising 7393 individuals from five countries [Brazil (n = 11), Argentina (n = 4), Chile (n = 1), Colombia (n = 1) and Peru (n = 1)] and two South-American collaborations. The pooled overall SVR12 rates [95% confidence interval (CI)] were 92.6% [90.2-94.7] and 95.5% [94.3-96.6] by ITT (11 studies; n = 4,153; I 2 = 84.2%) and per-protocol analysis (15 studies; n = 4,833; I 2 = 64.5%), respectively. The RR of SVR12 was similar in patients with or without HIV co-infection [4 studies; RR = 1.03 (0.99-1.07)] and those naive compared with treatment experimented-individuals [9 studies; RR = 1.01 (1.00-1.03)], but significantly higher in patients without cirrhosis compared with those with cirrhosis [11 studies; RR = 1.04

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of direct‐acting agents for chronic hepatitis C treatment in South America: A systematic review and meta‐analysis

Filho

Piedade

Castro

et al. 2020

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…Using a minimum dosage of medications, combination therapy may enhance the efficacy of drugs and can revive many drugs that halted during different drug development phases. 45,46 Danoprevir, inspired by the ciluprevir project, is also a 15-membered macrocyclic peptidomimetic inhibitor of nonstructural proteins (NS4A/NSP3). From a pharmaceutical perspective, the half-maximum inhibitory concentration (IC 50 ) and effective concentration (EC 50 ) of danoprevir are 0.2-0.4 nM and 1.6 nM, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Using a minimum dosage of medications, combination therapy may enhance the efficacy of drugs and can revive many drugs that halted during different drug development phases. 45 , 46 …”

Section: Discussionmentioning

confidence: 99%

A fuzzy logic-based computational method for the repurposing of drugs against COVID-19

2021

View full text Add to dashboard Cite

Introduction: COVID-19 has spread out all around the world and seriously interrupted human activities. Being a newfound disease, not only many aspects of the disease are unknown, but also there is not an effective medication to cure the disease. Besides, designing a drug is a time-consuming process and needs large investment. Hence, drug repurposing techniques, employed to discover the hidden benefits of the existing drugs, maybe a useful option for treating COVID-19. Methods: The present study exploits the drug repositioning concepts and introduces some candidate drugs which may be effective in controlling COVID-19. The suggested method consists of three main steps. First, the required data such as the amino acid sequences of targets and drug-target interactions are extracted from the public databases. Second, the similarity score between the targets (protein/enzymes) and genome of SARS-COV-2 is computed using the proposed fuzzy logic-based method. Since the classical approaches yield outcomes which may not be useful for the real-world applications, the fuzzy technique can address the issue. Third, after ranking targets based on the obtained scores, the usefulness of drugs affecting them is examined for managing COVID-19. Results: The results indicate that antiviral medicines, designed for curing hepatitis C, may also cure COVID-19. According to the findings, ribavirin, simeprevir, danoprevir, and XTL-6865 may be helpful in controlling the disease. Conclusion: It can be concluded that the similarity-based drug repurposing techniques may be the most suitable option for managing emerging diseases such as COVID-19 and can be applied to a wide range of data. Also, fuzzy logic-based scoring methods can produce outcomes which are more consistent with the real-world biological applications than others.

show abstract

Screening for Hepatitis C Virus Infection in Adolescents and Adults

Chou

Dana

et al. 2020

JAMA

View full text Add to dashboard Cite

IMPORTANCE A 2013 review for the US Preventive Services Task Force (USPSTF) of hepatitis C virus (HCV) screening found interferon-based antiviral therapy associated with increased likelihood of sustained virologic response (SVR) and an association between achieving an SVR and improved clinical outcomes. New direct-acting antiviral (DAA) regimens are available. OBJECTIVE To update the 2013 review on HCV screening to inform the USPSTF. DATA SOURCES Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews through February 2019, with surveillance through September 2019. STUDY SELECTION Randomized clinical trials (RCTs) and nonrandomized treatment studies of HCV screening and DAA therapy; cohort studies on screening, antiviral therapy, and the association between an SVR after antiviral therapy and clinical outcomes. DATA EXTRACTION AND SYNTHESIS One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality. MAIN OUTCOMES AND MEASURES Mortality, morbidity, quality of life, screening and treatment harms, and screening diagnostic yield. RESULTS Eight RCTs of DAA therapy vs placebo or an outdated antiviral regimen, 48 other treatment studies, and 33 cohort studies, with a total of 179 230 participants, were included. No study evaluated effects of HCV screening vs no screening. One new study since the 2013 review (n = 5917) found similar diagnostic yield of risk-based screening (sensitivity, 82%; number needed to screen to identify 1 HCV case, 15) and birth cohort screening (sensitivity, 76%; number needed to screen, 29), assuming perfect implementation. Ten open-label studies (n = 3292) reported small improvements in some quality-of-life and functional outcomes (eg, less than 3 points on the 0 to 100 36-Item Short Form Health Survey physical and mental component summary scales) after DAA treatment compared with before treatment. Two cohort studies (n = 24 686) found inconsistent associations of antiviral therapy vs no therapy with risk of hepatocellular carcinoma. Forty-nine treatment studies (n = 10 181) found DAA regimens associated with pooled SVR rates greater than 95% across genotypes, and low short-term rates of serious adverse events (1.9%) and withdrawal due to adverse events (0.4%). An SVR after antiviral therapy was associated with decreased adjusted risk of all-cause mortality (13 studies, n = 36 986; pooled hazard ratio [HR], 0.40 [95% CI, 0.28-0.56) and hepatocellular carcinoma (20 studies, n = 84 491; pooled HR, 0.29 [95% CI, 0.23 to 0.38]) vs no SVR. CONCLUSIONS AND RELEVANCE Direct evidence on the effects of HCV screening on clinical outcomes remains unavailable, but DAA regimens were associated with SVR rates greater than 95% and few short-term harms relative to older antiviral therapies. An SVR after antiviral therapy was associated with improved clinical outcomes compared with no SVR.

show abstract

Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial

Cited by 8 publications

References 22 publications

Effectiveness of direct‐acting agents for chronic hepatitis C treatment in South America: A systematic review and meta‐analysis

Effectiveness of direct‐acting agents for chronic hepatitis C treatment in South America: A systematic review and meta‐analysis

A fuzzy logic-based computational method for the repurposing of drugs against COVID-19

Screening for Hepatitis C Virus Infection in Adolescents and Adults

Contact Info

Product

Resources

About